Company Overview
Genomics BioSci & Tech Co., Ltd. (GM) is the first company in Taiwan to integrate genomic sequencing services with CRDMO (Contract Development and Manufacturing Organization) capabilities. Founded in 2001, the Company has long been dedicated to the fields of next-generation sequencing (NGS), multi-omics analysis, and nucleic acid-related technologies, providing one-stop integrated solutions spanning from basic research to clinical applications.
With the rapid growth of precision medicine and nucleic acid therapeutics, market demand for high-quality data, rapid turnaround, and integrated services continues to increase. Leveraging its solid technical foundation and well-established operational system, GM has gradually built a strong competitive position in the Asia-Pacific region. Its clients include academic institutions, hospitals, and biopharmaceutical companies, with applications covering basic research, clinical testing, and drug development. The Company continues to strengthen its capabilities from research through manufacturing, serving as a key partner across the industry value chain.
Service Offerings and Core Competencies
GM provides a comprehensive suite of services, including next-generation sequencing (NGS), multi-omics analysis (genomics, transcriptomics, and proteomics), bioinformatics, as well as nucleic acid and peptide synthesis and process development, forming a complete CRDMO service framework.
The Company offers both standardized and customized solutions to meet diverse customer needs across academic research, clinical testing, and drug development. Through integrated workflows spanning sample processing, data generation, and downstream analysis, GM enhances both project efficiency and data quality.
GM’s core strengths lie in its cross-platform integration capabilities, combining sequencing technologies with advanced bioinformatics to deliver high-quality data and actionable insights for research and clinical applications. By extending its capabilities into nucleic acid and peptide process development and small-batch, high-mix manufacturing, the Company enables a seamless transition from gene- related research (R) to development (D) and manufacturing (M), fully leveraging the CRDMO model.
Additionally, GM engages with clients early in the research and preclinical stages, supporting development strategies and fostering long-term partnerships. Its flexible, small-batch service model focuses on high-value, technically complex projects with diverse requirements, leveraging its strengths in customization, speed, and technical expertise.
Future Outlook
Looking ahead, GM will continue to advance its CRDMO capabilities by strengthening integrated services across gene-related research (R), development (D), and manufacturing (M), with a focus on high-value technologies. The Company will further enhance multi-omics integration, bioinformatics, and nucleic acid-related technologies to improve translational applications from basic research to clinical use.
As the nucleic acid therapeutics field continues to grow, GM will further develop its process development and manufacturing capabilities to support emerging therapeutic applications.
Overall, GM aims to strengthen its position as a CRDMO-driven service provider with integrated technology capabilities, supporting research and clinical applications across the life sciences industry.